possible synergies that could improve the effectiveness and efficiency of surveillance as a whole, including the implementation of new joint tools or the pooling of existing teams, tools or skills, especially in relation with information distribution, data management and outbreaks investigation. Assessing surveillance systems for animal diseases is necessary to ensure they meet their objectives and provide high-quality health information. OASIS is a standardized tool which facilitates comparison and readily highlights the individual strengths of each component as opportunities that could be extended to other components. This research has used the "OASIS Flash" method, which reduces the time required for the collection of information about the surveillance systems' operations and structure, compared with classical OASIS method. Our study is an original application of OASIS because several systems were evaluated simultaneously and compared. This approach requires minimal financial resources and is not very timeconsuming. Such a comparative evaluation could conceivably be applied to other surveillance systems, other industries and other countries. This approach would be especially relevant to enhance the efficiency of surveillance activities when resources are limited.
. The project is sub-divided into work packages (WP). WP1-'Constitution of a qualified sample collection' of "true positive" and "true negative". Special attention will be given to the inclusion of field samples from endemic countries like Brazil, India and Pakistan. WP2-'Producing standard sera for glanders'. Serum from glandered animals identified in WP1 will be collected to produce a large stock of positive sera as possibly international standard for glanders serodiagnosis. These sera will be available for the whole community as standard control reagents and will be included in the panel of sera for the validation pathway (WP3). WP3-'Serological tests validation following OIE validation pathway'. Performance of tests to be evaluated will be investigated in parallel using sera collected in WP1. The validation will include the analytical performance characteristics; repeatability, analytical specificity including exclusivity and exclusivity. All tests will be validated and compared regarding sensitivity using the same panel of true positive samples. The test specificity is the most discussed issue in glanders serological diagnosis. However, the sample collection for the validation will include negative samples from different regions. For example our partners from Pakistan (University of Agriculture, Fasialabad) and Brazil (Reference laboratory for Glanders, Recife) will contribute by providing large sample collections. Finally, for all tests the positive and negative predictive values should be calculable based on actual prevalence situation in the involved region, and allow to select the right test for the respective situation, as there are eradication scenarios, surveillance after being free of glanders, or for trade of animals. To contribute to the availability of the tests upon validation, companies will be encouraged to commercialize the ELISA and also transform the technology into a faster flow through assay (WP4). Equine viral arteritis (EVA) is a cause of abortion and neonatal deaths. In France, surveillance of EVA is based mostly on serological testing of all or part of the breeding horses, depending on the studbooks' regulations. Hence, EVA incidence is not precisely known in the overall breeding population. The first objective of this study was to estimate the number of EVA cases and outbreaks detected by the equine breeding stock surveillance between 2006 and 2013 in France, by establishing suitable rules for identification of seroconversion. The second objective was to assess the surveillance sensitivity, after having estimated the total number of outbreaks that occurred in breeding stock during this period using a capture-recapture model. Data from breeding mares which exhibited at least one positive result in serology using viral neutralization test between 2006 and 2013 were used for analysis (n¼1,645). Data consisted of the annual antibody titers and the location of the mares (towns). Seroconversion was defined as a change in antibody titer from negative to at least 32 or a three-fold increase. The number of seroconversions was counted for each town and modeled using an unilist zero-truncated binomial (ZTB) capture-recapture model with R software. The binomial denominator was the number of horses tested in each infected town. From 2006 to 2013, 239 cases of seroconversion located in 177 towns (outbreaks) were identified. During this period, the number of outbreaks in breeding stock was estimated at 1,482 (CI 95% 1,257-1,815) using the ZTB model. Consequently, it is estimated that over 1,000 outbreaks were not detected and the surveillance sensitivity at the town level was estimated around 12% (CI 95% 10%-14%). This study revealed a significant number of outbreaks in breeding stock. However, the surveillance sensitivity seems underestimated, especially due to lack of details related to the holdings, such as the number of at risk contacts or their precise address (the holdings list was not available and several holdings may be located within the same town). Nevertheless, the sensitivity could certainly be improved by including more breeding horses in the active surveillance. This study is the first in France to estimate the EVA incidence in breeding stock and to assess quantitatively the surveillance sensitivity. Moreover, the rules for identification of seroconversion defined in this study may be used to analyze other EVA surveillance datasets based on serology, such as testing before sales or international trade, and even compulsory or voluntary passive surveillance. Such rules, adjusted to the local environment, could conceivably be applied in other countries with EVA surveillance programs.
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